MedinCell S.A. (MEDCL.PA)
EUR 13.78
(1.85%)
EUR 13.78
(1.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -25.03 Million EUR | 21.78% |
| 2022 | -32 Million EUR | -29.04% |
| 2021 | -24.8 Million EUR | -30.65% |
| 2020 | -18.98 Million EUR | 20.61% |
| 2019 | -23.91 Million EUR | -21.48% |
| 2018 | -19.68 Million EUR | -105.69% |
| 2017 | -9.57 Million EUR | -168.77% |
| 2016 | -3.56 Million EUR | -672.51% |
| 2015 | 622 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -25.03 Million EUR | 21.78% |
| 2023 Q2 | -8.15 Million EUR | 0.0% |
| 2023 Q4 | -16.88 Million EUR | 0.0% |
| 2022 Q2 | -13.74 Million EUR | 0.0% |
| 2022 Q4 | -18.26 Million EUR | 0.0% |
| 2022 FY | -32 Million EUR | -29.04% |
| 2021 Q2 | -11.75 Million EUR | 0.0% |
| 2021 Q4 | -13.04 Million EUR | 0.0% |
| 2021 FY | -24.8 Million EUR | -30.65% |
| 2020 FY | -18.98 Million EUR | 20.61% |
| 2020 Q4 | -8.26 Million EUR | 0.0% |
| 2020 Q2 | -10.75 Million EUR | 0.0% |
| 2019 Q4 | -14.91 Million EUR | 0.0% |
| 2019 FY | -23.91 Million EUR | -21.48% |
| 2019 Q2 | -8.99 Million EUR | 0.0% |
| 2018 Q4 | -9.85 Million EUR | -100.0% |
| 2018 Q3 | -4.92 Million EUR | 49.86% |
| 2018 Q1 | -4.91 Million EUR | -4.4% |
| 2018 Q2 | -9.83 Million EUR | -100.0% |
| 2018 FY | -19.68 Million EUR | -105.69% |
| 2017 Q2 | -4.86 Million EUR | -100.0% |
| 2017 Q4 | -4.7 Million EUR | -100.0% |
| 2017 FY | -9.57 Million EUR | -168.77% |
| 2017 Q3 | -2.35 Million EUR | 51.59% |
| 2017 Q1 | -2.43 Million EUR | 0.0% |
| 2016 FY | -3.56 Million EUR | -672.51% |
| 2015 FY | 622 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -611.711% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 83.053% |
| Adocia SA | -21.16 Million EUR | -18.316% |
| Aelis Farma SA | -5.07 Million EUR | -393.068% |
| Biophytis S.A. | -17.02 Million EUR | -47.057% |
| Advicenne S.A. | -7.03 Million EUR | -256.109% |
| genOway Société anonyme | 1.56 Million EUR | 1697.244% |
| IntegraGen SA | -171.39 Thousand EUR | -14508.02% |
| Medesis Pharma S.A. | -3.95 Million EUR | -532.354% |
| Neovacs S.A. | -8.74 Million EUR | -186.363% |
| NFL Biosciences SA | -3.74 Million EUR | -568.486% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 31726.015% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -689.606% |
| Sensorion SA | -22.06 Million EUR | -13.482% |
| Theranexus Société Anonyme | -6.82 Million EUR | -266.699% |
| TME Pharma N.V. | -6.73 Million EUR | -271.704% |
| Valbiotis SA | -7.36 Million EUR | -239.821% |
| TheraVet SA | -1.57 Million EUR | -1494.059% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -23.073% |
| DBV Technologies S.A. | -67.26 Million EUR | 62.78% |
| Genfit S.A. | -28.89 Million EUR | 13.345% |
| GeNeuro SA | -14.75 Million EUR | -69.669% |
| Innate Pharma S.A. | -7.57 Million EUR | -230.753% |
| Inventiva S.A. | -110.42 Million EUR | 77.326% |
| MaaT Pharma SA | -19.71 Million EUR | -26.987% |
| Nanobiotix S.A. | -39.7 Million EUR | 36.932% |
| OSE Immunotherapeutics SA | -23 Million EUR | -8.847% |
| Poxel S.A. | -35.09 Million EUR | 28.646% |
| GenSight Biologics S.A. | -26.22 Million EUR | 4.508% |
| Transgene SA | -22.32 Million EUR | -12.137% |
| Valneva SE | -101.42 Million EUR | 75.315% |